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under-shoot the goal AUC (-12.8 % vs. +19.5 %, P ¼ .018), and
require busulfan dose increases (+20% vs. -19.9%, P ¼ .012)
compared to those dosed on actual body weight. A subgroup
analysis conﬁrmed this result for patients receiving Bu/Cy
(-23.6 % vs. +2.2%, P ¼<.001 for goal AUC and +36.2% vs. -4.5
%, P ¼ .008 for busulfan dose changes in adjusted vs. actual
body weight groups, respectively), but not Flu/Bu condi-
tioning regimens (-0.8 % vs. +25.3%, P¼ .123 for goal AUC and
+3.4% vs. -25.1 %, P ¼ .174 for busulfan dose changes in
adjusted vs. actual body weight groups, respectively).
Notably, two patients dosed by actual body weight in the Flu/
Bu group experienced an AUC of > 9000 mmol*min. Time to
neutrophil or platelet engraftment, progression-free survival
and overall survival were not signiﬁcantly different between
those dosed on actual versus adjusted body weight (P > .05).
No neurologic adverse events or VOD incidents were
observed in any group.
Conclusions: Our prospective analysis of IV busulfan
PK data in various myeloablative and non-myeloablative
busulfan based conditioning regimens for HSCT provides
important insight into the choice of appropriate busulfan
dosing weight. Further studies are warranted to elucidate
which weight is most likely to achieve goal area-
under-the curve and subsequent optimal patient
outcomes.541
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Background: Etoposide is an important drug in the
conditioning regimen for hematopoietic stem cell trans-
plant (HSCT). The administration of etoposide in this
patient care setting presents a challenge due to limited
aqueous solubility. As a result of the high doses utilized in
myeloablative regimens, administration is accompanied
by large volumes of intravenous ﬂuids which increase
the risk for volume overload, cardiac dysfunction, and
electrolyte abnormalities. There are published reports
that describe unchanged pharmacokinetic parameters
between diluted and undiluted drug, as well as data
describing the safe use of undiluted drug in the transplant
population.
Methods: We report our experience with eleven patients
who received undiluted etoposide (20 mg/mL) over 4 hours
through a central line in preparation for HSCT. All patients
received an antihistamine and corticosteroid as premed-
ication, as well as another dose of each and acetaminophen
when half of the volume had infused. The etoposide was
infused through DEHP-free tubing into a dedicated lumen.
Vital signs were monitored at baseline, regularly
throughout the infusion, and after the infusion was
complete.
Results: Between April 2 and June 15, 2012, eleven
patients received undiluted etoposide at a dose of 60 mg/
kg. The most common adverse events documented were
gastrointestinal toxicities. All patients reported nausea
and most cases were accompanied by emesis, requiring an
average of 4.4 antiemetic doses for treatment of break-
through nausea/vomiting. Hypotension was documentedin nine patients, with an average drop in systolic blood
pressure of 35 mm Hg (range: 15-46 mm Hg) occurring 6.6
hours (range: 1.7-18.8 hours) after the start of etoposide
infusion. Nine patients required ﬂuid resuscitation with an
average of 1400 mL (range: 500 mL-3500 mL) of normal
saline.
Conclusion: Despite published reports of successful
administration of undiluted etoposide in myeloablative
conditioning regimens, we report numerous adverse events
in our patient population. All patients treated at our insti-
tution with undiluted etoposide as part of the conditioning
regimen experienced side effects related to the drug. The
beneﬁts of administering undiluted etoposide should be
carefully weighed against the possibility of related tox-
icities.542
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Introduction: Antifungal prophylaxis with azoles is con-
sidered standard in patients undergoing allo-HCT. However,
azoles have signiﬁcant interactions with immunosuppres-
sive drugs used for graft-versus-host disease (GVHD)
prophylaxis. Since the risk of GVHD is increased in the
setting of sub-therapeutic immunosuppressant levels, we
changed our standard practice from initiating the triazole on
day +3 to day +7 after allo-HCT in order to make the change
at steady state and limit the occurrence of non-therapeutic
levels.
Methods:We retrospectively evaluated 196 patients treated
from Jan 2009 to Nov 2011 to assess the impact of delaying
the start of azole antifungals on immunosuppressive levels,
acute GVHD, and rate of invasive fungal infections (IFI).
Micafungin was given from admission until azole initiation.
Patients received voriconazole (n¼162), posaconazole
(n¼17), ﬂuconazole (n¼9) or were maintained on mica-
fungin (n¼8). Stem cell sources included PBSCT from
related/unrelated donors (n¼139) and cord blood grafts
(n¼57). GVHD prophylaxis was with tacrolimus (tacro) +
sirolimus (siro) + methotrexate (MTX) (n¼76), tacro + MTX
(n¼42), cyclosporine (CSA) + mycophenolate mofetil (MMF)
(n¼57), tacro + MMF (n¼9), tacro + siro (n¼7), CSA + MTX
(n¼3), CSA (n¼1), siro + MMF (n¼1). Results were analyzed
by intent-to-treat (ITT) for patients treated before (day+3
switch, n¼69) or after February 2010 (day+7 switch, n¼127)
as well as by actual day of switch + 1 (day+2,3,4: n¼49 vs.
day+6,7,8: n¼70). Cumulative incidence (CI) functions esti-
mated day 200 grade II-IV aGVHD. Gray's test was used to
compare aGVHD incidence for individuals in the day +3 and
day+7 treatment categories for both the ITT and as-treated
analyses.
Results: Median levels two weeks after HCT were thera-
peutic in 19/19 (100%), 50/52 (96%), 31/32 (97%) patients on
CSA, Tacro, and Siro, respectively, prior to Feb 2010 and in
43/44 (98%), 82/83 (99%), 47/52 (90%), for CSA, Tacro, and
